CRM (cardiac rhythm management) sales drive Medtronic's strong performance
This article was originally published in Clinica
Medtronic's fourth-quarter sales were $27m better than estimates by analysts at Morgan Stanley. This was due largely to strong cardiac rhythm management sales, together with better-than-expected vascular sales, although these were still weak, the analysts said. Cardiac rhythm management sales were a record $2.94bn in the year and $832m in the quarter, up 13% and 18%, respectively. Traditional pacing sales were weak, but the company had strong sales of its InSync device for congestive heart failure, as well as better than expected sales of traditional ICD products, the analysts said. Medtronic's vascular unit sales were $206m in the quarter, down 16%, but up 10% sequentially, the company said.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.